Revenue
2017
2018
2019
2020
2021
2022
2023
2024
Tvardi Therapeutics, Inc. (TVRD)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $7.1M | $21.0M | $41.9M | $23.0M | $135.1M | $19.9M | $13.5M | $911,000 | $86,000 | $3.8M | $3.2M | $12.0M | $1.2M |
| Research & development | $18.0M | $23.6M | $108.5M | $91.9M | $82.7M | $107.9M | $113.8M | $75.5M | $48.5M | $49.3M | $21.2M | $15.1M | $8.7M | $4.6M |
| Operating expenses | $26.7M | $28.1M | $142.5M | $129.4M | $112.1M | $129.7M | $131.6M | $90.9M | $60.4M | $58.5M | $29.0M | $21.2M | $12.2M | $7.4M |
| Operating income | −$26.7M | −$28.1M | −$121.5M | −$87.5M | −$89.1M | $5.4M | −$111.7M | −$77.4M | −$59.5M | −$58.4M | −$25.2M | −$18.1M | −$237,000 | −$6.2M |
| EBITDAderived | −$26.7M | −$28.0M | −$121.2M | −$87.3M | −$88.8M | $5.6M | −$111.5M | −$77.0M | −$59.0M | −$56.9M | −$24.3M | −$17.3M | $552,000 | −$5.2M |
| Net income | −$18.2M | −$29.4M | −$118.5M | −$85.5M | −$88.4M | $8.4M | −$106.4M | −$74.0M | −$58.1M | −$57.3M | −$24.7M | −$17.7M | −$4.0M | −$6.3M |
| Basic EPSper diluted share | -$2.46 | -$11.42 | -$26.26 | -$19.12 | -$1.74 | $0.18 | -$2.49 | -$2.06 | -$1.86 | -$2.10 | -$1.00 | -$0.85 | -$0.74 | — |
| Diluted EPSper diluted share | -$3.26 | -$11.42 | -$26.26 | -$19.12 | -$1.74 | $0.18 | -$2.49 | -$2.06 | -$1.86 | -$2.10 | -$1.00 | -$0.85 | -$0.74 | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 28, 2025Form 4 | Posner ChristopherPRESIDENT AND CEO | SellCommon Stock | 583 | $4.75 | $2.8K | 13.1K |
| Feb 28, 2025Form 4 | Terrillion ScottSEC'Y; CHIEF COMPLIANCE & G.C. | SellCommon Stock | 163 | $4.76 | $775.88 | 7.2K |
| Feb 4, 2025Form 4 | Posner ChristopherPRESIDENT AND CEO | SellCommon Stock | 372 | $4.72 | $1.8K | 13.7K |
| Nov 4, 2024Form 4 | Posner ChristopherPRESIDENT AND CEO | SellCommon Stock | 3.7K | $0.29 | $1.1K | 168.8K |
| Aug 1, 2024Form 4 | Posner ChristopherPRESIDENT AND CEO | SellCommon Stock | 4.1K | $0.35 | $1.5K | 172.4K |